MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/jmedgenet-2017-104863

Медицинская библиотека · Journal of medical genetics · 2018

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.

Arends Maarten, Biegstraaten Marieke, Wanner Christoph, Sirrs Sandra, Mehta Atul, Elliott Perry M, Oder Daniel, Watkinson Oliver T, Bichet Daniel G, Khan Aneal, Iwanochko Mark, Vaz Frédéric M, van Kuilenburg André B P, West Michael L, Hughes Derralynn A, Hollak Carla E M

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Two recombinant enzymes (agalsidase alfa 0.2 mg/kg/every other week and agalsidase beta 1.0 mg/kg/every other week) have been registered for the treatment of Fabry disease (FD), at equal high costs. An independent international initiative compared clinical and biochemical outcomes of the two enzymes.

METHODS

In this multicentre retrospective cohort study, clinical event rate, left ventricular mass index (LVMI), estimated glomerular filtration rate (eGFR), antibody formation and globotriaosylsphingosine (lysoGb3) levels were compared between patients with FD treated with agalsidase alfa and beta at their registered dose after correction for phenotype and sex.

RESULTS

387 patients (192 women) were included, 248 patients received agalsidase alfa. Mean age at start of enzyme replacement therapy was 46 (±15) years. Propensity score matched analysis revealed a similar event rate for both enzymes (HR 0.96, P=0.87). The decrease in plasma lysoGb3 was more robust following treatment with agalsidase beta, specifically in men with classical FD (β: -18 nmol/L, P<0.001), persisting in the presence of antibodies. The risk to develop antibodies was higher for patients treated with agalsidase beta (OR 2.8, P=0.04). LVMI decreased in a higher proportion following the first year of agalsidase beta treatment (OR 2.27, P=0.03), while eGFR slopes were similar.

CONCLUSIONS

Treatment with agalsidase beta at higher dose compared with agalsidase alfa does not result in a difference in clinical events, which occurred especially in those with more advanced disease. A greater biochemical response, also in the presence of antibodies, and better reduction in left ventricular mass was observed with agalsidase beta.

Для цитирования: Arends Maarten, Biegstraaten Marieke, Wanner Christoph, Sirrs Sandra, Mehta Atul, Elliott Perry M, Oder Daniel, Watkinson Oliver T, Bichet Daniel G, Khan Aneal, Iwanochko Mark, Vaz Frédéric M, van Kuilenburg André B P, West Michael L, Hughes Derralynn A, Hollak Carla E M. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.. Journal of medical genetics. 2018. DOI: 10.1136/jmedgenet-2017-104863.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.